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A B S T R A C T
This study aimed to establish the safety of chemotherapy use in pregnant women with 
breast cancer, and to find possible effects in the fetus. A search of MEDLINE/PubMed, 
LILACS, SciELO, Cochrane, UpToDate, and Google Scholar databases was performed to 
identify publications., 86 articles published from 2001 to 2012 were retrieved and evaluated 
by two readers in accordance predetermined exclusion and inclusion criteria; 39 articles 
were selected . All the chemotherapy drugs used to treat breast cancer during pregnancy 
belonged to class D, and consisted of 5-fluorouracil (F), doxorubicin (A) or epirubicin (E) 
and cyclophosphamide (C), or the combination doxorubicin and cyclophosphamide (AC), 
a safe regimen when used after the first trimester of pregnancy. Few studies evaluated 
the use of taxanes (T), such as docetaxel (D) and paclitaxel (P), with no increase in the 
occurrence of fetal defects and other maternal complications when used in the second and 
third trimesters of pregnancy. The use of trastuzumab in pregnant women is associated 
with oligohydramnios and anhydramnios; thus, it is not recommended during pregnancy. 
As almost all studies were observational and retrospective, new prospective studies on the 
subject are needed.
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
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Introduction
Breast cancer is defined as associated with pregnancy when 
it is diagnosed during pregnancy, breastfeeding, or within the 
first year after birth. It is a challenging setting with a delicate 
management, whose treatment often generates problems and 
distress for the pregnant woman, her family, and health care 
professionals involved due to the dilemma created between the 
optimum therapy for the mother and well-being of the fetus. 
Delaying the treatment, with protection of the fetus in mind, 
may impair maternal health.1-3
Breast cancer incidence may rise in coming years due to 
the secular trend of lower parity and first birth delay, brought 
about by changes in the lifestyle of modern women. Studies 
indicate that the incidence of pregnancy associated with 
breast cancer ranges from 1:3,000 to 1:10,000 pregnancies; the 
disease is mostly diagnosed in an advanced stage and has a 
worse prognosis than in non-pregnant women.1,4,5 In Sweden, 
an increase was observed between 1963 and 2002 from 16 to 
37.4 per 100,000 births, that is, an absolute frequency of 
1,161 cases of breast cancer associated with pregnancy.6
The goal of treating pregnant women with breast cancer is 
the same pursued for non-pregnant women: local control of 
the disease and prevention of systemic metastases. However, 
the treatment mode needs to be carefully evaluated in view 
of the potential adverse effects on the fetus.1 Surgery seems 
to be reasonably safe, and is the ultimate treatment for breast 
carcinoma in pregnant women. The surgery risks during 
pregnancy include miscarriage and preterm birth, with no 
increased risk of congenital defects.4,5
Radiation therapy should be delayed whenever possible 
until the postpartum period. Most pregnant women with breast 
cancer are candidates for systemic chemotherapy. Recent 
evidence suggests that several agents used in breast cancer 
treatment present a good safety profile, particularly when they 
are started after the first trimester of pregnancy, resulting in 
live births and low morbidity.2,3,5,7,8
This study aims to identify in the scientific literature 
evidence related to chemotherapy safety in pregnant women 
with breast cancer, and to find possible effects for the mother 
and the fetus.
Methods
A wide literature review was performed, searching digital 
databases. Publications in MEDLINE/PubMed were identified 
through the following search strategy: (“Breast Neoplasms” 
[MeSH] AND “Pregnancy Complications, Neoplastic” [MeSH] 
AND (“Drug Therapy” [MeSH] OR “Chemotherapy, Adjuvant” 
[MeSH]) AND (“humans” [MeSH Terms]) AND (“women” 
[MeSH Terms] OR “female” [MeSH Terms]); 76 articles were 
retrieved. For the LILACS, SciELO, Cochrane, and Google 
Scholar researches, the following keywords were used: 
breast neoplasms, pregnancy, chemotherapy, câncer de 
mama, gravidez, and quimioterapia; 10 additional articles were 
retrieved.
No randomized studies were retrieved, probably due to the 
low prevalence of the disease during pregnancy, which led to 
the inclusion of descriptive studies, since almost all articles 
retrieved were retrospective studies, case reports, and case 
series. Overall, the search resulted in 86 articles published 
between 2001 and 2012. The articles were evaluated by two 
readers who applied predefined exclusion and inclusion 
criteria, resulting in a final selection of 27 articles. The 
following inclusion criteria were considered: 1) pregnant 
patients; 2) patients had breast cancer; 3) the study addressed 
chemotherapy as treatment for breast cancer during preg-
nancy; 4) the article was written in English, Portuguese, 
Spanish, or French; 5) the study described systemic effects of 
chemotherapy on mother and fetus.
Câncer de mama na gravidez e quimioterapia: revisão sistemática
R E S U M O
O objetivo do estudo é estabelecer a segurança do uso da quimioterapia na gestante portadora 
de câncer de mama e verificar as possíveis intercorrências no feto. Para identificação de 
publicações foi realizada pesquisa bibliográfica nas bases de dados: MEDLINE/PubMed, 
LILACS, SciELO, Cochrane, Uptodate e Google acadêmico. A busca totalizou 86  artigos 
publicados de 2001 a 2012, que foram avaliados por dois revisores obedecendo aos critérios 
de exclusão e inclusão pré-estabelecidos, sendo selecionados 39 artigos para a elaboração 
deste estudo. Todos os quimioterápicos utilizados no tratamento do câncer de mama na 
gravidez pertencem à categoria D, consistindo no uso de 5-fluorouracil (F), doxorrubicina (A) 
ou epirrubicina (E) e ciclofosfamida (C) ou na combinação de doxorrubicina e ciclofosfamida 
(AC), método seguro quando utilizado após o primeiro trimestre da gestação. Poucos estudos 
avaliaram o uso de taxanos (T) como docetaxel (D) e paclitaxel (P), não sendo demonstrado 
aumento da ocorrência de malformações fetais e outras complicações maternas quando 
utilizados no segundo e terceiro trimestres da gestação. O uso do trastuzumabe em 
gestantes encontra-se associado à oligodramnia e adramnia, não sendo recomendado na 
gravidez. Em função da quase totalidade dos estudos serem observacionais e retrospectivos, 
torna-se necessário a confecção de novos estudos prospectivos sobre o tema.
Palavras-chave:
Câncer de mama
Gravidez
Quimioterapia
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Studies published before 2001, those whose complete text 
was not available, and those that evaluated puerperal patients 
solely, addressed other treatments for pregnant women with 
breast cancer, evaluated non-pregnant patients, were written 
in foreign languages other than those mentioned, or assessed 
fertility and the possibility of pregnancy after chemotherapy 
were excluded. 12 other references were used to assist in 
elaborating the introduction and the discussion of results.
Figure 1 details the selection of articles used to make this 
study.
Results
The most often used chemotherapy regimen during the second 
or third trimester of pregnancy consists of 5-fluorouracil (F), 
doxorubicin (A) or epirubicin (E) and cyclophosphamide (C), or 
of the combination doxorubicin and cyclophosphamide (AC), 
all of which are considered class D in pregnancy.
Of the articles that met the selection criteria for this study, 
12 addressed the use of these drugs; those chemotherapy 
regimens had the highest number of related studies. Epirubicin 
is the structural analog of doxorubicin, and has the advantage 
of causing less heart toxicity. Chemotherapy use in the first 
trimester is associated with malformations in 10% to 20% of 
fetuses, including micrognathia, hand and foot defects, and 
ventriculomegaly;9,10 however, it has been shown to be safe 
after that period (Table 1).
No data are available regarding the optimum dosage 
in regimens containing anthracyclines during pregnancy, 
whether or not associated with taxanes. The use of taxanes 
(T), such as docetaxel (D) and paclitaxel (P), was reported in five 
studies, and they appear to offer a limited risk to both mother 
and fetus, but their safety is poorly documented. Paclitaxel 
pharmacokinetics were studied in a case of twin pregnancy, 
with low fetal exposition to the drug.18
In the studies reviewed, no significant differences in 
maternal and perinatal results were identified with these drugs 
(Table 2).
Published data regarding trastuzumab use in pregnant 
women with breast cancer are included in ten case reports. 
In four, trastuzumab was used in association with other 
drugs, such as tamoxifen, docetaxel, and vinorelbine.23-26 The 
other six reports used transtuzumab alone. The time in the 
pregnancy when the drug was used varied among the studies.
The available evidence in these reports strongly suggests 
that the use of trastuzumab leads to reduced amniotic fluid 
volume, since in eight of ten studies oligohydramnios or 
anhydramnios was observed. In only one of the reports the 
amniotic fluid was found to be normal after discontinuation of 
the drug;27 fetal death occurred in three of them (Table 3).23,28,29
Discussion
Most pregnant women with breast cancer are candidates for 
chemotherapy. Due to the serious consequences for maternal 
health when treatment is delayed, pregnancy should not be 
considered a deterrent to appropriate therapy.1,2,3,33 Overall, 
these patients can be treated in accordance with the guidelines 
set for the treatment in non-pregnant women. However, it is 
important to stress that almost all chemotherapy drugs used 
belong to class D, that is, they are potentially harmful for 
the developing fetus, but the requirements of treatment can 
warrant their use.
The informed consent is essential in approaching the 
case. The patient and her family should be informed of the 
therapeutic options and respective risks, and the treatment 
decision should be made together. Although pregnancy 
termination may be considered after the diagnosis of breast 
cancer, there is no evidence that it is necessary in order to 
improve maternal-fetal prognosis.33 The approach must be 
individualized, mainly as a consequence of the gestational age 
and the patient’s clinical condition.
The 27 studies selected in this review were observational. 
Most (25/27) were case reports or case series. This type of 
study is particularly used in infrequently seen clinical settings, 
such as breast cancer during pregnancy. They are applied to 
document uncommon medical events and can represent the 
first evidence to identify new conditions or adverse effects, 
e.g., teratogenic effects on the fetus in mothers undergoing 
chemotherapy during pregnancy.34 The low incidence of this 
condition prevents other study designs that might generate 
better-quality scientific evidence, such as interventional 
studies/trials. Thus, the current review is limited by the quality 
of the studies included, due to a lack of more robust studies 
on the subject.
The therapy regimen most often used by pregnant women 
with breast cancer includes the anthracyclines epirubicin 
and doxorubicin, combined with cyclophosphamide and 
5-fluorouracil (Table 1). This therapeutic regimen was used in 
12 of the studies included in this review, describing 124 cases. 
Of these, only 4 cases underwent chemotherapy in the first 
trimester: there was one case of miscarriage3 and 2 cases of 
malformed neonates.9,10 There is also a report on one case with 
normal neonate after chemotherapy in all three trimesters 
of pregnancy.16 Despite the impossibility of a causative 
association between chemotherapy treatment in the first 
trimester and the malformations found, there is a consensus 
on avoiding its use during this period. New studies to assure 
the safety of using these drugs in early pregnancy are needed.
The study including the greatest number of cases of pregnant 
women with breast cancer treated with the FAC regimen in 
the second and third trimesters (57) showed that 40 women 
reached disease-free survival (three had recurrences, 12 died 
from breast cancer, one died from another cause, and one was 
lost to follow-up). All fetuses exposed to the therapy were live 
births with no malformations, except for three cases: one had 
Down syndrome, one had congenital clubfoot, and one had 
bilateral ureteral reflux. The small size of the sample impairs 
the comparison with the incidence of these alterations in the 
general population, and does not allow the causal association 
with the use of chemotherapy drugs is set. The authors 
reported no significant neonatal complications. The most 
common neonatal complication was supplemental oxygen, 
required in 10% of neonates, presumably due to prematurity. 
One neonate had a subarachnoid hemorrhage on the second 
day after vaginal delivery. Regarding long-term adverse effects, 
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such as fertility, cognition, and heart function disorders, the 
cases presented in this study did not have complications 
and presented evidences of normal development throughout 
the study period. These infants’ follow-up ranged from 2 to 
157 months. The authors concluded that using the FAC 
regimen during the second and third trimesters of pregnancy 
is safe and well-tolerated.5 Another study of 26 cases, with a 
follow-up for up to 84 months also did not evidence remote 
adverse effects.7
Regarding taxanes use, there are not many literature 
reports describing their use in pregnant women with breast 
cancer. Taxanes are a group of antineoplastic drugs with 
antimitotic activity that appear to improve the prognosis for 
women with breast cancer, particularly those having node 
involvement.35 Animal studies demonstrate that these drugs 
may cause fetal demise and intrauterine growth restriction, in 
addition to conditions related to ossification.20 However, none 
of the five case reports selected in this review demonstrated 
neonate involvement from medication use in the second 
and third trimesters (Table 2). One report on a fetus with 
hydrocephalus spontaneously reversed after birth. It is 
important to highlight, however, that the use of docetaxel 
Study/Year Study Design Sample Substance  
(n)
Pregnancy 
period
Maternal  
effects
GA  
at birth
Fetal effects 
Leyder et al. (2011)9 Case report  1 FEC
FMC
1st trim.
2nd trim.
− 19 w Micrognathia/hand  
and foot defects
Logue (2009)11 Case report  1 FAC 3rd trim. − 37 w Normal neonate
Sharma et al. (2009)12 Case report  1 FEC 3rd trim. Leucopenia 36 w Normal neonate
Azim et al. (2008)7 Cohort 26 E (23) 2nd trim. − ±35 w Normal neonates
A (3)
Hahn et al. (2006)5 Cohort 57 FAC 2nd and  
3rd trim.
− ±37 w 97% normal neonates  
(1 Down syndrome,  
1 clubfoot, 1 ureteral reflux)
Skrablin et al. (2005)13 Case report  1 AC 2nd trim. − 37 w Normal neonate
Ring et al. (2005)3 Case series 28 A (16) 2nd trim. 1 miscarriage 37 w Normal neonates
FMC (12)
Mathelin et al. (2005)14 Case report  2 FA 2nd trim. − 37 w Normal neonates
Kerr (2005)15 Case report  1 AC 2nd trim. − 31 w Normal neonate
Paskulin et al. (2005)10 Case report  1 FAC 1st trim. − 38 w Ventriculomegaly, high  
palate, microcephaly,  
syndactyly, deficient  
growth and development
Andreadis et al. 
(2004)16
Case report  1 FEC-1st trim./
associated with 
RT/AZ/TX
1st, 2nd,  
and  
3rd trim.
Anemia 
hyperemesis
35 w Normal neonate
Kuerer (2002)17 Case report  4 FAC 3rd trim. − 36 w Normal neonates
1st trim., 1st trimester of pregnancy; 2nd trim., 2nd trimester of pregnancy; 3rd trim, third trimester of pregnancy; A, doxorubin; 
AC, doxorubicin + cyclophosphamide; AZ, zolendronic acid; C, cyclophosphamide; E, epirubicin; F, 5-fluorouracil; RT, radiation therapy (28 Gy);  
TX, tamoxifeno.
Table 1 − Evaluation of maternal and fetal effects of using 5-fluorouracil, doxorubicin or epirubicin, 
and cyclophosphamide.
A total of 86 articles were identified 
by electronic media
32 articles excluded for their abstract
54 articles remained 
and were later evaluated 
by two readers
11 review articles and 1 textbook
27 articles excluded by inclusion 
and exclusion criteria
39 articles selected
Fig. 1 − Flowchart explaining the bibliographic research and article selection.
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by this patient occurred from 26 weeks of pregnancy and, by 
this time, hydrocephalus had already been diagnosed.20 One 
patient with a twin pregnancy had contractions at the second 
docetaxel cycle, and nifedipino was used in subsequent cycles. 
The pregnancy proceeded uneventfully, and a C-section was 
performed at 38 weeks.18
A systematic literature review conducted in 2010 evidenced 
a favorable toxicity profile for taxanes during the second and 
third trimesters of pregnancy. However, as pregnancy induces 
pharmacokinetic changes, the conclusion was that taxane 
efficacy is limited, thus suggesting that new studies assessing 
the pharmacokinetics, as well as placental crossing, are needed 
to confirm the safety profile in pregnant women with breast 
cancer.36
Trastuzumab is a monoclonal antibody targeting the 
human epidermal growth factor receptor 2 (HER2). When this 
receptor is highly expressed, it leads to increased cell growth 
and proliferation, thus indicating that the breast tumor is more 
aggressive. Treatment with trastuzumab showed better outcomes 
and survival in the treatment of HER2-positive breast tumors.37
Study/Year  Study  
Design
Sample Substance  
(n)
Pregnancy  
period
Maternal  
effects
GA  
at birth
Fetal effects 
Beale et al. (2009)23 Case report 1 (twin) Trastuzumab + 
tamoxifeno
1st and  
2nd trim.
Oligohydramnios
PL and PROM
32 w Kidney injury –  
1st twin death at  
age of three months
Azim et al. (2009)30 Case report 1 Trastuzumab Preconcep.  
and 1st trim.
None 39 w N development within 
fourteen months
Pant et al. (2008)31 Case report 1 Trastuzumab 1st and  
2nd trim.
Oligohydramnios 32 w N development  
within five years
Weber & Schaefer 
(2008)28
Case report 1 Trastuzumab 1st and  
2nd trim.
Oligohydramnios
PA
27 w < kidney perfusion, 
death at the age  
of four months
Bader et al. (2007)24 Case report 1 Trastuzumab + 
paclitaxel
2nd and  
3rd trim.
Oligohydramnios
Reduced fetal renal 
function
32 w Neonatal sepsis, 
transient respiratory 
failure
Witzel et al. (2008)29 Case report 1 Trastuzumab 2nd and  
3rd trim.
Oligohydramnios  
and vaginal bleeding
28 w Respiratory failure, 
capillary fragility,  
and neonatal death
Sekar et al. (2007)25 Case report 1  Trastuzumab  
and docetaxel
2nd and  
3rd trim.
Reversed 
oligohydramnios
36 w
IUGR
Shrim et al. (2007)32 Case report 1 Trastuzumab 1st and  
2nd trim.
Reversed heart  
failure
37 w Transient tachypnea,  
N development  
within two months
Fanale et al. (2005)26 Case report 1 Trastuzumab  
and Vironelbine
2nd and  
3rd trim.
Oligohydramnios 34w N development  
within six months
Watson et al. (2005)27 
 
Case report 
 
1 
 
Trastuzumab 
 
1st and  
2nd trim. 
Reversed 
oligohydramnios after 
drug withdrawal
37 w 
 
N development  
within six months 
1st trim., 1st trimester of pregnancy; 2nd trim., 2nd trimester of pregnancy; 3rd trim, third trimester of pregnancy; IUGR, intrauterine growth 
restriction; N, normal; PA, placental abruption; PL, premature labor; PROM, premature rupture of membranes.
Table 3 − Evaluation of effects of trastuzumab use on the mother and the fetus.
Study/Year Study Design Sample Substance (n) Pregnancy period Maternal effects GA at birth Fetal effects
Nieto et al. (2006)19 Case report 1 FAC + docetaxel 2nd and 3rd trim. − 39 w Normal neonate
Lycette et al. (2006)18 Case report 1 (twin) Docetaxel 2nd and 3rd trim. TPL 38 w Normal neonate, 
up to 16-month 
follow-up
Potluri et al. (2006)20 Case report 2 AC+ docetaxel 2nd and 3rd trim. Preeclampsia 34 w Reversed 
hydrocephalus, N 
28-month follow-up
35 w Normal neonate, 
9-month follow-up
Gonzalez-Angulo  
et al. (2004)21
Case report 1 AC+ docetaxel 2nd and 3rd trim. Preeclampsia 37 w Normal neonate, 
12-month follow-up
Gadducci et al.  
(2003)22
Case report 1 E+ paclitaxel 2nd and 3rd trim. − 36 w Normal neonate, 
36-month follow-up
2nd trim., 2nd trimester of pregnancy; 3rd trim, third trimester of pregnancy; N, normal; TPL, threatened premature labor.
Table 2 − Evaluation of effects of docetaxel and paclitaxel use on the mother and the fetus.
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The studies in pregnant women with breast cancer 
demonstrated an association with oligohydramnios or 
anhydramnios. One hypothesis to explain this reduced fluid 
volume is trastuzumab’s secondary effect on the fetal renal 
epithelium, where epidermal growth factor receptors are 
highly expressed, and are blocked by this drug,30,31 leading 
to a decreased fetal urinary output, which was evidenced 
by empty fetal bladder visualization in the presence of 
echografically-normal kidneys.. Pant et al.31 suggested that this 
oligohydramnios might be secondary to an altered expression 
of vascular endothelial growth factor (VEGF), which regulates 
amniotic fluid production and reabsorption by changing fetal 
membrane permeability.
Regarding the neonatal course, six cases of admission to 
a neonatal unit were observed.23,24,28,29,32 Irreversible kidney 
failure with demise of the first twin,23 respiratory failure 
and capillary fragility with neonatal death29, and decreased 
kidney perfusion with death at the age of four months 
were reported.28 Other cases were successfully managed, 
with further normal development.26,27,30-32 Trastuzumab 
administration is associated with cardiotoxicity, with reduced 
ventricular ejection fraction.38 Only one case of reversible heart 
failure was reported in the review.32 However, information on 
maternal heart evaluation is found only in two other studies 
describing normal maternal echocardiograms.27,30
Thus, data regarding trastuzumab use in pregnancy are 
limited to few case reports, impairing conclusions. There 
were no malformation reports, although unfavorable neonatal 
outcomes have occurred. It is important to stress the prevalent 
observation of oligohydramnios, making thorough monitoring 
of the amniotic fluid volume, a fetal kidney function marker 
and a fetal well-being indicator, a mandatory measure in 
cases where the drug is an option. Likewise, maternal heart 
condition should be monitored due to the known cardiotoxicity 
of trastuzumab. Thus, trastuzumab use during pregnancy, 
especially extended use, is not encouraged,38 and should be 
restricted to cases where treatment benefits for the mother 
outweigh pulmonary hypoplasia, skeletal abnormalities, 
kidney injury, and neonatal death risks.23,27,29,36
When planning the therapy for pregnant women, delivery 
is scheduled within two or three weeks after the last chemo-
therapy cycle, in order to avoid maternal and/or fetal neutro-
penia, and thus reducing the risk of complications.5
The selection of a chemotherapy regimen to treat metastatic 
disease is extremely controversial, and experts prefer to use 
anthracyclic drugs. Evidence shows that anthracycline use 
is safe in the second and third trimesters of pregnancy, with 
evidence level 2B (Oxford Level of Evidence [LOE] 2B). Given 
the lack of scientific evidence, recommendations of new 
cytotoxic drugs during pregnancy, such as taxanes, are not 
the consensu (LOE 5),8 and trastuzumab use should also be 
avoided.23,25,27,29,31,36
The prospect of a future pregnancy is important for young 
women with breast cancer. Studies show that pregnancy 
occurrence in women with previous breast cancer history after 
successful management has no significant impact on survival. 
A metanalysis including 1,244 women who conceived after 
breast cancer treatment and 18,145 controls confirmed these 
results and suggested that pregnancy after breast cancer may 
have a protective effect, with a reduction of death risk by 42% 
(OR = 0.42), compared with the group that did not conceive 
after cancer treatment.39
Conversely, there are cases of patients with breast cancer 
that conceive during chemotherapy with potentially teratogenic 
drugs. This demonstrates the importance of contraception 
in women of reproductive age requiring chemotherapy, 
through an intrauterine device, barrier methods, or combined 
non-hormonal methods.
Recommendations
1.  Chemotherapy in pregnant women with breast cancer 
should not be delayed, and additional care should be taken 
to protect the fetus.
2.  Chemotherapy can be safely administered during the 
second and third trimesters with minimal risk to the fetus.
3.  Regimens based on anthracycline use should be preferred.
4.  Chemotherapy should be avoided within three or four 
weeks from delivery in order to prevent neonatal transient 
myelosuppression.
5.  Trasutuzumab use is not recommended during pregnancy, 
due to the risk of oligohydramnios, anhydramnios, fetal 
pulmonary hypoplasia, skeletal and developmental 
abnormalities, and fetal demise.
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